Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Corixa Corporation (NasdaqNM:CRXA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug  9Earnings Announcement
Location
1124 Columbia Street, Suite 200
Seattle, WA 98104
Phone: (206) 754-5711
Fax: (206) 754-5715
Email: investor.relations@corixa.com
Employees (last reported count): 538
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 31%
·Over the last 6 months:
 · one insider buy; 15.0K shares (0.1% of insider shares)
·Institutional: 44% (63% of float)
(189 institutions)
·Net Inst. Buying: 2.32M shares (+11.50%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Corixa Corporation is a developer of immunotherapies with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. The Company has a broad range of technology platforms, which enable both integrated vaccine product design and the use of its separate proprietary technologies (antigens, monoclonal antibodies, adjuvants, antigen delivery technology and tumor activated peptide, or TAP, pro-drug technology) on a standalone, POWERED BY CORIXA basis. The Company exploits its expertise in immunology and its proprietary technology platforms to discover and develop vaccines, antigen-based products, including therapeutic antibodies, novel adjuvants and targeted oncologics.
More from Market Guide: Expanded Business Description

Financial Summary
Corixa is a research-based biotechnology company committed to the goal of treating and preventing diseases by understanding and directing the immune system. For the six months ended 6/30/01, revenues rose 67% to $29.1 million. Net loss before acct. change and applicable to Common totalled $75 million, up from $17.3 million. Results reflect revenue recognized from collaborative agreements with GlaxoSmithKline, offset by increased payroll and personnel expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Steven Gillis, Ph.D., 47
Chairman, CEO
$440K
Michael Bigham, 43
Vice Chairman
--  
Michelle Burris, 35
CFO, Sr. VP
--  
Steven Reed, Ph.D., 50
Exec. VP, CSO
266K
Kenneth Grabstein, Ph.D., 50
Exec. VP of Immunology
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CRXAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 3-Apr-2001
$6.25 
Recent Price$11.65 
52-Week High
on 5-Sep-2000
$54.00 
Beta1.95 
Daily Volume (3-month avg)376.1K
Daily Volume (10-day avg)169.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-78.2%
52-Week Change
relative to S&P500
-70.8%
Share-Related Items
Market Capitalization$477.9M
Shares Outstanding41.0M
Float28.3M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$8.41 
Earnings (ttm)-$33.02 
Earnings (mrq)-$0.79 
Sales (ttm)$1.58 
Cash (mrq)$3.01 
Valuation Ratios
Price/Book (mrq)1.39 
Price/EarningsN/A 
Price/Sales (ttm)7.38 
Income Statements
Sales (ttm)$48.7M
EBITDA (ttm)-$698.2M
Income available to common (ttm)-$728.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-211.05%
Return on Equity (ttm)-274.72%
Financial Strength
Current Ratio (mrq)2.77 
Debt/Equity (mrq)0.08 
Total Cash (mrq)$123.5M
Short Interest
As of 8-Aug-2001
Shares Short3.53M
Percent of Float12.5%
Shares Short
(Prior Month)
3.67M
Short Ratio8.62 
Daily Volume409.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.